EGFR and non-small cell lung carcinoma: In summary, our commentary pointed out significant clinical improvements in ORR and PFS in the PAPILLON study (amivantamab + platinum-based chemotherapy vs. chemotherapy alone), supporting the use of this regimen as the potential standard-of-care in the first-line treatment of EGFR exon 20 insertion-positive NSCLC patients [40].